----

**EXHIBIT      31.2**

**CERTIFICATION      OF CFO PURSUANT TO SECTION 302**

**OF      THE SARBANES-OXLEY ACT OF 2002**

|  |   | I,                    Diane Dottavio, certify                    that: |
|--|--------|------------------------------------------------------------------------|

|  | 1. | I                have reviewed this annual report on Form 10-K of Endovasc,                Inc.; |
|--|----|--------------------------------------------------------------------------------------------------|

|  | 2. | Based                on my knowledge, this report does not contain any untrue statement                of a                material fact or omit to state a material fact necessary to make                the                statements made, in light of the circumstances under which such statements                were made, not misleading with respect to the period covered by this                report; |
|--|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 3. | Based                on my knowledge, the financial statements, and other financial information                included in this report, fairly present in all material respects                the                financial condition, results of operations and cash flows of Endovasc,                Inc. as of, and for, the periods presented in this                report; |
|--|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 4. | Endovasc,                Inc.'s other certifying officer and                I: |
|--|----|--------------------------------------------------------------------------------|

|  | a) | are                responsible for establishing and maintaining disclosure controls                and                procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e))                for                Endovasc, Inc and have: |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | b) | designed                such disclosure controls and procedures, or caused such disclosure                controls and procedures to be designed under our supervision, to                ensure                that material information relating to Endovasc, Inc., including its                consolidated subsidiaries, is made known to us by others within those                entities, particularly during the period in which this report is                being                prepared; |
|--|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | c) | evaluated                the effectiveness of Endovasc, Inc.’s disclosure controls and procedures                and presented in this report our conclusions about the effectiveness                of                the disclosure controls and procedures, as of the end of the period                covered by this report based on such evaluation;                and |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | d) | Disclosed                in this report any change in Endovasc, Inc.’s internal control over                financial reporting that occurred during Endovasc, Inc.’s most recent                fiscal year that has materially affected, or is reasonably likely                to                materially affect, Endovasc, Inc.’s internal control over financial                reporting; and |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | 5. | Endovasc,                Inc.’s other certifying officer and I have disclosed, based on our most                recent evaluation of internal control over financial reporting, to                Endovasc, Inc.'s auditors and the audit committee of Endovasc, Inc.’s                Board of Directors (or persons performing the equivalent                functions): |
|--|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | a) | all                significant deficiencies and material weaknesses in the design or                operation of internal control over financial reporting which are                reasonably likely to adversely affect Endovasc, Inc.’s ability to record,                process, summarize and report financial information;                and |
|--|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | b) | any                fraud, whether or not material, that involves management or other                employees who have a significant role in Endovasc, Inc.’s internal control                over financial reporting. |
|--|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:                October 12, 2006 | /s/                Diane Dottavio          |   |
|---------------------------------------|--------------------------------------------|--------|
|                                  | **Diane                Dottavio,**         |   |
|                                  | **Chief                Financial Officer** |   |
|                                  | **Chairman                of the Board**   |   |

----